Ofatumumab is first self-administered, targeted B-cell treatment for relapsing MS. The first self-administered, targeted B-cell treatment for relapsing multiple sclerosis (MS) received FDA approval
Stem Cells therapy
What is the latest treatment for ALS?
There are currently two approved drugs to treat ALS: riluzole, which can extend lifespan by an average of a few months and has been on the market for 25 years, and the 2017-approved edaravone, which Read more…
